Mr. Metselaar was trained as a pharmacist at the faculty of Pharmaceutical Sciences at the Utrecht University and invented the liposomal corticosteroid technology platform. From 2005 on he managed the company’s research projects, patent portfolio and daily operations. He leads the pharmaceutical development of the company´s proprietary technology into clinical applicable products.
Mr. Rutten has 17 years of experience in management, business development and marketing in the biotechnology industry. His previous experience include positions within large and small biotechnology organizations in the U.S., Netherlands, Asian Pacific, India, Canada, and Mexico. Mr Rutten currently is director of Clinquest Services, co-founder of Audion Therapeutics, a company targeting hearing loss and of Dybly, a cardiovascular therapeutics company based in Basel, Switzerland. Mr. Rutten received his Masters in Biotechnology from the University of Wageningen in the Netherlands.
Dr. Wortel has 25 years of experience in the development of biopharmaceuticals and innovative medical technologies. Dr. Wortel’s experience includes both international academic and industrial pharmaceutical research. He has served as a senior medical research executive for several companies, including Centocor, Inc. and Alkermes, Inc. During his tenure at Centocor, Dr. Wortel was responsible for the development of Remicade®, and at Alkermes, he was responsible for the development of Nutropin Depot™. His industry experience includes the oversight of international medical operations under stringent SOP and GCP standards, and he is internationally recognized for his expertise in the design and analysis of clinical trials. He is the Founder of the Clinquest Group of companies. Dr. Wortel trained at the University of Amsterdam, and received his PhD in Immunology in 1993. His academic experience also includes training in the specialties of Cardiology, Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research.